Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.

Saved in:
Bibliographic Details
Title: Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
Authors: Demarest JF; Clear Creek Bio, Cambridge, MA, USA., Kienle M; Clear Creek Bio, Cambridge, MA, USA., Boytz R; NEIDL, Boston University, Boston, MA, USA., Ayres M; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA., Kim EJ; University of Louisville, Louisville, KY, USA., Patten JJ; NEIDL, Boston University, Boston, MA, USA., Chung D; University of Louisville, Louisville, KY, USA., Gandhi V; Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA., Davey RA; NEIDL, Boston University, Boston, MA, USA., Sykes DB; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA., Shohdy N; Clear Creek Bio, Cambridge, MA, USA., Pottage JC Jr; Clear Creek Bio, Cambridge, MA, USA., Kumar VS; Clear Creek Bio, Cambridge, MA, USA. Electronic address: brq@clearcreekbio.com.
Source: Antiviral research [Antiviral Res] 2022 Oct; Vol. 206, pp. 105403. Date of Electronic Publication: 2022 Aug 28.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8109699 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-9096 (Electronic) Linking ISSN: 01663542 NLM ISO Abbreviation: Antiviral Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-9096
DOI:10.1016/j.antiviral.2022.105403